Outcomes measures
Bleeding, sICH
BLEEDING, SECONDARY, INTRACEREBRAL HEMORRHAGE
This analysis used the same primary and all applicable secondary efficacy analyses used for the parent trial. The primary efficacy outcome measure was the proportion of patients functionally independent (modified Rankin Scale [mRS] score of 0 to 2) at 90 days. The mRS score is an ordered scale ranging from 0 (no symptoms) to 6 (death).Secondary efficacy outcomes included a shift analysis of the mRS score at 90 days; the proportion of patients disability‐free (mRS score 0 to 1); the change of the NIHSS score from baseline to 24 h and 5–7 days (or at discharge if earlier); the score of the European Quality of Life 5‐Dimension 5‐level scale (EQ‐5D‐5L; a higher score indicates a better quality of life) at 90 days. Safety outcomes included incidence of symptomatic intracerebral hemorrhage (sICH) according to Heidelberg Bleeding Classification,